JP6893173B2 - Ｃｎｓ障害を処置するための組成物および方法 - Google Patents
Ｃｎｓ障害を処置するための組成物および方法 Download PDFInfo
- Publication number
- JP6893173B2 JP6893173B2 JP2017528154A JP2017528154A JP6893173B2 JP 6893173 B2 JP6893173 B2 JP 6893173B2 JP 2017528154 A JP2017528154 A JP 2017528154A JP 2017528154 A JP2017528154 A JP 2017528154A JP 6893173 B2 JP6893173 B2 JP 6893173B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(CC1)([C@@](CC2)C(CC3)C1[C@@](CC1)[C@@]3C[C@@]1(O)I)[C@]2C(C1(CCC*=C)*CC1)=O Chemical compound CC(CC1)([C@@](CC2)C(CC3)C1[C@@](CC1)[C@@]3C[C@@]1(O)I)[C@]2C(C1(CCC*=C)*CC1)=O 0.000 description 24
- IMRWILPUOVGIMU-UHFFFAOYSA-N Brc1ncccc1 Chemical compound Brc1ncccc1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- KZAQVQJKRXZYKK-MBKVACPOSA-N CC(C)([C@@H](CC1)[C@@](C)(CC2)[C@]1(C)[C@H](CC1)[C@@]2(C)[C@@H](CC2)[C@H]1C[C@]2(C)O)c1cnccc1 Chemical compound CC(C)([C@@H](CC1)[C@@](C)(CC2)[C@]1(C)[C@H](CC1)[C@@]2(C)[C@@H](CC2)[C@H]1C[C@]2(C)O)c1cnccc1 KZAQVQJKRXZYKK-MBKVACPOSA-N 0.000 description 1
- LFPPIWMEAAXRLW-UHFFFAOYSA-N CC(C)CC(C)N(C)OC Chemical compound CC(C)CC(C)N(C)OC LFPPIWMEAAXRLW-UHFFFAOYSA-N 0.000 description 1
- WPJPSYHNDMBZKW-ZYEQNNROSA-N CC(Oc(cc1)ccc1C([C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@]2(C)O)=N)(F)F Chemical compound CC(Oc(cc1)ccc1C([C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@]2(C)O)=N)(F)F WPJPSYHNDMBZKW-ZYEQNNROSA-N 0.000 description 1
- DBTCVTWICOWTAO-LGOYVUFDSA-N CCc(cc1)ccc1C([C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@]2(C)[C@H]1CC(C)(C)CC2)=O Chemical compound CCc(cc1)ccc1C([C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@]2(C)[C@H]1CC(C)(C)CC2)=O DBTCVTWICOWTAO-LGOYVUFDSA-N 0.000 description 1
- XYZWMVYYUIMRIZ-UHFFFAOYSA-N CN(C)c(cc1)ccc1Br Chemical compound CN(C)c(cc1)ccc1Br XYZWMVYYUIMRIZ-UHFFFAOYSA-N 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N COc1cccc(N)c1 Chemical compound COc1cccc(N)c1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- ITPWADYSOCLNTA-ILSCHMRGSA-N C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1c[s]cc1)=O Chemical compound C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1c[s]cc1)=O ITPWADYSOCLNTA-ILSCHMRGSA-N 0.000 description 1
- PSLHTBSZNHOGDF-JYQNWREZSA-N C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1ccc(C)cc1)=N Chemical compound C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1ccc(C)cc1)=N PSLHTBSZNHOGDF-JYQNWREZSA-N 0.000 description 1
- VJYRHFJHIQBMRJ-BLGFVBJKSA-N C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@H](CC2)[C@@]1(C)[C@H]2C(c1nc(cccc2)c2[s]1)=O Chemical compound C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@H](CC2)[C@@]1(C)[C@H]2C(c1nc(cccc2)c2[s]1)=O VJYRHFJHIQBMRJ-BLGFVBJKSA-N 0.000 description 1
- KAULIZSEWDCUCV-BHDSADDHSA-N C[C@@H](CC1)C[C@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1ncccc1)=N Chemical compound C[C@@H](CC1)C[C@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1ncccc1)=N KAULIZSEWDCUCV-BHDSADDHSA-N 0.000 description 1
- WFCVTFUINOLPLV-OVVBHJHBSA-N C[C@@H](CC[C@]1(C)[C@@H](CC[C@]2(C)[C@H](CC3)C(c(cc4)ccc4SC)=N)[C@@](C)(CC4)[C@@]23N)C[C@]14N Chemical compound C[C@@H](CC[C@]1(C)[C@@H](CC[C@]2(C)[C@H](CC3)C(c(cc4)ccc4SC)=N)[C@@](C)(CC4)[C@@]23N)C[C@]14N WFCVTFUINOLPLV-OVVBHJHBSA-N 0.000 description 1
- JDJYBSSMKXYWBA-ROEXDCMRSA-N C[C@H](CC1)[C@](C)(CC[C@@H](CCC2)[C@@H](CC3)[C@@H]2C[C@]3(C)O)[C@H]1C(c(cc1)ccc1OC)=O Chemical compound C[C@H](CC1)[C@](C)(CC[C@@H](CCC2)[C@@H](CC3)[C@@H]2C[C@]3(C)O)[C@H]1C(c(cc1)ccc1OC)=O JDJYBSSMKXYWBA-ROEXDCMRSA-N 0.000 description 1
- YJGOWFOYWPTEJL-QCJJQSFCSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)C3C[C@]1(C)O)[C@H]2C(c1ccccc1F)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)C3C[C@]1(C)O)[C@H]2C(c1ccccc1F)=O YJGOWFOYWPTEJL-QCJJQSFCSA-N 0.000 description 1
- SNMFIDPVGVJPFS-DZCPYTMKSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1OC)=O SNMFIDPVGVJPFS-DZCPYTMKSA-N 0.000 description 1
- XXNBWGJEPGPCSR-VEMLKXGYSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)C#N)[C@H]2C(c(cc1)ccc1-c1ccccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)C#N)[C@H]2C(c(cc1)ccc1-c1ccccc1)=O XXNBWGJEPGPCSR-VEMLKXGYSA-N 0.000 description 1
- BOBXFKPVTXBFDX-XKKDOOBNSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H]1[C@H]3CC(C)(C)CC1)[C@H]2C(c1cnc[nH]1)=[U] Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H]1[C@H]3CC(C)(C)CC1)[C@H]2C(c1cnc[nH]1)=[U] BOBXFKPVTXBFDX-XKKDOOBNSA-N 0.000 description 1
- AFOVZRJRFJJSCN-QTLXGVTLSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(CC1)[C@@H]3C[C@]1(C)O)C2C(c(cccc1)c1-c1ccccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(CC1)[C@@H]3C[C@]1(C)O)C2C(c(cccc1)c1-c1ccccc1)=O AFOVZRJRFJJSCN-QTLXGVTLSA-N 0.000 description 1
- FYJYRINIHYGALP-GXPHRRQYSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C1=C(C)CCS1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C1=C(C)CCS1)=O FYJYRINIHYGALP-GXPHRRQYSA-N 0.000 description 1
- VYWDCPPMWFIJCU-WAHCFVBASA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1c(C)cccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1c(C)cccc1)=O VYWDCPPMWFIJCU-WAHCFVBASA-N 0.000 description 1
- PFVILKBBBIITMG-ROIBLFINSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H]1[C@H]3CC(C)(C)CC1)[C@H]2C(c1cc(OC)ccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H]1[C@H]3CC(C)(C)CC1)[C@H]2C(c1cc(OC)ccc1)=O PFVILKBBBIITMG-ROIBLFINSA-N 0.000 description 1
- YDUKUYRDNOIQBA-LSBZSBGNSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1Cl)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1Cl)=O YDUKUYRDNOIQBA-LSBZSBGNSA-N 0.000 description 1
- WWZHJUNHNDBLRT-JEJYNDPUSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)C2C(c1c(C)cccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)C2C(c1c(C)cccc1)=O WWZHJUNHNDBLRT-JEJYNDPUSA-N 0.000 description 1
- UXTNTNONGLSRPS-RGYBDQPCSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O UXTNTNONGLSRPS-RGYBDQPCSA-N 0.000 description 1
- IOSGZVVLXFCLDP-SCNDPVEVSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cccc([I]=C)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cccc([I]=C)c1)=O IOSGZVVLXFCLDP-SCNDPVEVSA-N 0.000 description 1
- LEOLRQXBZFHWNP-XIGAYJBWSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC[C@](C)(C1)O)[C@]31N)[C@H]2C(c1ccc(C)cc1)=C Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC[C@](C)(C1)O)[C@]31N)[C@H]2C(c1ccc(C)cc1)=C LEOLRQXBZFHWNP-XIGAYJBWSA-N 0.000 description 1
- FBNRZEDRVUANJQ-RLZHEZGZSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@]1(C)[C@@H]3CC(C)(C)CC1)[C@H]2C(C)=N Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@]1(C)[C@@H]3CC(C)(C)CC1)[C@H]2C(C)=N FBNRZEDRVUANJQ-RLZHEZGZSA-N 0.000 description 1
- PRAJXDJPZHMACZ-LUUFTWKVSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC[C@@]3(C[C@@](C)(CC4)O)N)[C@H]1[C@]34N)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC[C@@]3(C[C@@](C)(CC4)O)N)[C@H]1[C@]34N)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O PRAJXDJPZHMACZ-LUUFTWKVSA-N 0.000 description 1
- QVSKBEIYSCNDSZ-VUXXRCJTSA-N C[C@](CC1)([C@H](CC[C@@](C2)(C3(C)CC[C@@]2(C)O)C=C)[C@@]3(CC2)N)[C@@]2(C)[C@H]1C(O)=O Chemical compound C[C@](CC1)([C@H](CC[C@@](C2)(C3(C)CC[C@@]2(C)O)C=C)[C@@]3(CC2)N)[C@@]2(C)[C@H]1C(O)=O QVSKBEIYSCNDSZ-VUXXRCJTSA-N 0.000 description 1
- QZVGSGRVYIQMNK-UHFFFAOYSA-N C[n]1ncc([BrH]C)c1 Chemical compound C[n]1ncc([BrH]C)c1 QZVGSGRVYIQMNK-UHFFFAOYSA-N 0.000 description 1
- IPWBFGUBXWMIPR-UHFFFAOYSA-N Fc(cccc1)c1Br Chemical compound Fc(cccc1)c1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021090965A JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2022189056A JP2023022187A (ja) | 2014-11-27 | 2022-11-28 | Ｃｎｓ障害を処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014092369 | 2014-11-27 | ||
| CNPCT/CN2014/092369 | 2014-11-27 | ||
| PCT/CN2015/095765 WO2016082789A1 (en) | 2014-11-27 | 2015-11-27 | Compositions and methods for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021090965A Division JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535586A JP2017535586A (ja) | 2017-11-30 |
| JP2017535586A5 JP2017535586A5 (enExample) | 2019-01-10 |
| JP6893173B2 true JP6893173B2 (ja) | 2021-06-23 |
Family
ID=56073637
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528154A Active JP6893173B2 (ja) | 2014-11-27 | 2015-11-27 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2021090965A Active JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2022189056A Pending JP2023022187A (ja) | 2014-11-27 | 2022-11-28 | Ｃｎｓ障害を処置するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021090965A Active JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2022189056A Pending JP2023022187A (ja) | 2014-11-27 | 2022-11-28 | Ｃｎｓ障害を処置するための組成物および方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10774108B2 (enExample) |
| EP (2) | EP3719029A1 (enExample) |
| JP (3) | JP6893173B2 (enExample) |
| CY (1) | CY1123200T1 (enExample) |
| DK (1) | DK3224269T3 (enExample) |
| ES (1) | ES2793237T3 (enExample) |
| HR (1) | HRP20200840T1 (enExample) |
| HU (1) | HUE049014T2 (enExample) |
| LT (1) | LT3224269T (enExample) |
| ME (1) | ME03749B (enExample) |
| PL (1) | PL3224269T3 (enExample) |
| PT (1) | PT3224269T (enExample) |
| RS (1) | RS60343B1 (enExample) |
| SI (1) | SI3224269T1 (enExample) |
| SM (1) | SMT202000276T1 (enExample) |
| WO (1) | WO2016082789A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021130698A (ja) * | 2014-11-27 | 2021-09-09 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| KR102121633B1 (ko) | 2012-08-21 | 2020-06-10 | 세이지 테라퓨틱스, 인크. | 간질 또는 간질지속 상태를 치료하는 방법 |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| HUE051403T2 (hu) | 2013-04-17 | 2021-03-01 | Sage Therapeutics Inc | Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz |
| LT3021852T (lt) | 2013-07-19 | 2021-04-12 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas |
| EP3035940B1 (en) | 2013-08-23 | 2018-10-17 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN112961206A (zh) | 2014-10-16 | 2021-06-15 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| EP3206493B1 (en) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA43284A (fr) * | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| JP6947743B2 (ja) * | 2016-03-03 | 2021-10-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用 |
| NZ790225A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
| NZ790187A (en) * | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| IL315950A (en) | 2016-08-23 | 2024-11-01 | Sage Therapeutics Inc | 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| WO2019126741A1 (en) * | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3852764A4 (en) * | 2018-09-19 | 2022-06-15 | ModernaTX, Inc. | STEROL ANALOGUES AND USES THEREOF |
| CN109369762B (zh) * | 2018-10-31 | 2021-06-18 | 湖南玉新药业有限公司 | 17-甲酸甾族化合物的制备方法 |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| US11337987B1 (en) | 2021-05-07 | 2022-05-24 | Lipocine Inc. | Compositions and methods for treating central nervous system disorders |
| US12208103B1 (en) | 2021-05-07 | 2025-01-28 | Lipocine Inc. | Compositions and methods for treating CNS disorders |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| FR1380417A (fr) | 1962-05-15 | 1964-12-04 | Roussel Uclaf | Nouveaux androstanyl-pyrazoles et procédé de préparation |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1380246A (en) * | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| GB1434919A (en) | 1972-06-15 | 1976-05-12 | Glaxo Lab Ltd | 3alpha-hydroxy androstanes |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1436324A (en) * | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2438020A1 (de) | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JPH06510999A (ja) | 1991-09-13 | 1994-12-08 | コセンシス・インコーポレイテッド | ステロイド結合部位を有する新規ＧＡＢＡ↓ａレセプター |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| DE69518509T2 (de) | 1994-02-14 | 2001-04-19 | Euro-Celtique S.A., Luxemburg/Luxembourg | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| JP2002500616A (ja) | 1994-07-21 | 2002-01-08 | ファルマシア・アンド・アップジョン・カンパニー | 神経学的に活性なアミノステロイド |
| WO1996016076A1 (en) | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| CZ394197A3 (cs) | 1995-06-06 | 1998-06-17 | Cocensys, Inc. | Neuroaktivní steroidy androstanové a pregnanové řady |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| JP3877961B2 (ja) * | 1998-03-11 | 2007-02-07 | ベクストルム，トルビエーン | Ｃｎｓ疾患の治療におけるエピアロプレグナノロン |
| WO2000066614A1 (en) | 1999-04-29 | 2000-11-09 | Purdue Pharma Ltd. | 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| PT1172371E (pt) | 2000-02-18 | 2005-10-31 | Taiho Pharmaceutical Co Ltd | Preparacao de derivados esteroides |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| US6844456B2 (en) | 2000-11-03 | 2005-01-18 | Washington University | Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| MXPA05010339A (es) | 2003-03-24 | 2005-12-14 | Sterix Ltd | Derivados de estrogeno como inhibidores de la esteroide sulfatasa. |
| US7781421B2 (en) | 2003-05-29 | 2010-08-24 | Washington University | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods |
| WO2005051972A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Estrogen receptor modulators |
| US20090118248A1 (en) | 2004-04-23 | 2009-05-07 | Euro-Celtique S.A. | 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| CA2582231A1 (en) | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals, Inc. | Steroid analogs and uses |
| PL1888080T3 (pl) | 2005-06-09 | 2010-09-30 | Euro Celtique Sa | Kompozycje farmaceutyczne neuroaktywnego steroidu i jego zastosowanie |
| MX2009005335A (es) * | 2006-11-21 | 2009-06-08 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc. |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| JP5663303B2 (ja) | 2007-06-15 | 2015-02-04 | リサーチ トライアングル インスティテュート | Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| WO2010054158A2 (en) | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| WO2012013816A1 (en) | 2010-07-30 | 2012-02-02 | Medexis S.A. | Compounds and methods for treating neoplasia |
| AU2011343615A1 (en) | 2010-12-15 | 2013-05-09 | Harbor Biosciences, Inc. | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| US9457033B2 (en) | 2011-02-15 | 2016-10-04 | Socpra Sciences Et Genie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
| CZ303443B6 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| US9851309B2 (en) | 2011-03-23 | 2017-12-26 | Satoshi Watabe | Ultra-high-sensitive assay of protein and nucleic acid and kit, and novel enzyme substrate |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| HRP20192348T1 (hr) | 2012-01-23 | 2020-03-20 | Sage Therapeutics, Inc. | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil eter beta-ciklodekstrina |
| WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3336097B1 (en) | 2012-06-19 | 2020-08-19 | Intercept Pharmaceuticals, Inc. | Preparation of the non-crystalline form of obeticholic acid |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| KR102121633B1 (ko) | 2012-08-21 | 2020-06-10 | 세이지 테라퓨틱스, 인크. | 간질 또는 간질지속 상태를 치료하는 방법 |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| US9757391B2 (en) * | 2012-11-09 | 2017-09-12 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| DK2925327T3 (da) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| HRP20181048T1 (hr) | 2012-12-18 | 2018-08-24 | Washington University | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| CA2831054C (en) | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury |
| GB201302368D0 (en) | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169831A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| HUE051403T2 (hu) | 2013-04-17 | 2021-03-01 | Sage Therapeutics Inc | Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| LT3021852T (lt) | 2013-07-19 | 2021-04-12 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas |
| EP3035940B1 (en) | 2013-08-23 | 2018-10-17 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| TWI839649B (zh) | 2014-05-29 | 2024-04-21 | 美商賽吉醫療公司 | 神經活性類固醇，其組合物及其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10172870B2 (en) | 2014-09-02 | 2019-01-08 | The Texas A&M University System | Method of treating organophosphate intoxication by administration of neurosteroids |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP3206493B1 (en) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CN112961206A (zh) | 2014-10-16 | 2021-06-15 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| HUE049014T2 (hu) | 2014-11-27 | 2020-09-28 | Sage Therapeutics Inc | Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3280420B1 (en) | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| WO2017044659A1 (en) | 2015-09-08 | 2017-03-16 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| EP3362042A1 (en) | 2015-10-16 | 2018-08-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| MA43284A (fr) | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| CA3017172C (en) | 2016-03-08 | 2023-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| NZ790225A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| IL315950A (en) | 2016-08-23 | 2024-11-01 | Sage Therapeutics Inc | 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| CN111065394B (zh) | 2017-08-31 | 2023-03-31 | 武田药品工业株式会社 | 中枢神经系统病症的治疗 |
| SG11202002085YA (en) | 2017-09-07 | 2020-04-29 | Sage Therapeutics Inc | Neuroactive steroids and their methods of use |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| EP3681510A1 (en) | 2017-09-14 | 2020-07-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| EP3706755A4 (en) | 2017-11-10 | 2021-11-10 | Marinus Pharmaceuticals, Inc. | GANAXOLONE FOR USE IN THE TREATMENT OF GENETIC EPILEPTIC DISORDERS |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| JP2021506904A (ja) | 2017-12-22 | 2021-02-22 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害の処置のための組成物および方法 |
| WO2019126741A1 (en) | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JP7538040B2 (ja) | 2018-01-12 | 2024-08-21 | セージ セラピューティクス， インコーポレイテッド | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
| MA52894A (fr) | 2018-06-12 | 2021-04-21 | Sage Therapeutics Inc | 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci |
| DK3864022T3 (da) | 2018-10-12 | 2023-12-18 | Sage Therapeutics Inc | Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser |
| EP4606812A3 (en) | 2018-10-19 | 2025-10-15 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| US20230322846A9 (en) | 2018-12-05 | 2023-10-12 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| EP3898646A1 (en) | 2018-12-21 | 2021-10-27 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| TWI855081B (zh) | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| MX2021015854A (es) | 2019-06-27 | 2022-04-18 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del snc. |
| US20230303616A9 (en) | 2019-06-27 | 2023-09-28 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| BR112021026447A2 (pt) | 2019-06-27 | 2022-04-12 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios de cns |
| IL293510A (en) | 2019-12-05 | 2022-08-01 | Sage Therapeutics Inc | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| CN115551874A (zh) | 2020-03-18 | 2022-12-30 | 萨奇治疗股份有限公司 | 神经活性类固醇及其使用方法 |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| CA3183248A1 (en) | 2020-06-24 | 2021-12-30 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
| BR112023000990A2 (pt) | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
| WO2022115381A1 (en) | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Onc. | Compositions and methods for treating cns disorders cross reference to related application |
| EP4284382A1 (en) | 2021-01-28 | 2023-12-06 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| US20240148756A1 (en) | 2021-02-18 | 2024-05-09 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| TW202300156A (zh) | 2021-03-17 | 2023-01-01 | 美商賽吉醫療公司 | 用於治療重度憂鬱症之19-nor-c3,3-二取代c21-n-吡唑基類固醇 |
| EP4322960A1 (en) | 2021-04-12 | 2024-02-21 | Sage Therapeutics, Inc. | Treatment of essential tremor |
| AU2022267304A1 (en) | 2021-04-29 | 2023-11-02 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| AU2022266680A1 (en) | 2021-04-29 | 2023-11-02 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
-
2015
- 2015-11-27 HU HUE15862506A patent/HUE049014T2/hu unknown
- 2015-11-27 WO PCT/CN2015/095765 patent/WO2016082789A1/en not_active Ceased
- 2015-11-27 HR HRP20200840TT patent/HRP20200840T1/hr unknown
- 2015-11-27 PL PL15862506T patent/PL3224269T3/pl unknown
- 2015-11-27 PT PT158625061T patent/PT3224269T/pt unknown
- 2015-11-27 DK DK15862506.1T patent/DK3224269T3/da active
- 2015-11-27 LT LTEP15862506.1T patent/LT3224269T/lt unknown
- 2015-11-27 SM SM20200276T patent/SMT202000276T1/it unknown
- 2015-11-27 US US15/531,313 patent/US10774108B2/en active Active
- 2015-11-27 EP EP20159317.5A patent/EP3719029A1/en not_active Ceased
- 2015-11-27 ES ES15862506T patent/ES2793237T3/es active Active
- 2015-11-27 JP JP2017528154A patent/JP6893173B2/ja active Active
- 2015-11-27 EP EP15862506.1A patent/EP3224269B1/en active Active
- 2015-11-27 SI SI201531219T patent/SI3224269T1/sl unknown
- 2015-11-27 ME MEP-2020-105A patent/ME03749B/me unknown
- 2015-11-27 RS RS20200610A patent/RS60343B1/sr unknown
-
2020
- 2020-02-25 US US16/800,053 patent/US20210017218A1/en not_active Abandoned
- 2020-05-26 CY CY20201100480T patent/CY1123200T1/el unknown
-
2021
- 2021-05-31 JP JP2021090965A patent/JP7186259B2/ja active Active
-
2022
- 2022-10-04 US US17/959,592 patent/US11945836B2/en active Active
- 2022-11-28 JP JP2022189056A patent/JP2023022187A/ja active Pending
-
2024
- 2024-02-20 US US18/581,595 patent/US20250042934A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021130698A (ja) * | 2014-11-27 | 2021-09-09 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
| JP7186259B2 (ja) | 2014-11-27 | 2022-12-08 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK3224269T3 (da) | 2020-05-25 |
| US20170342102A1 (en) | 2017-11-30 |
| JP2017535586A (ja) | 2017-11-30 |
| PL3224269T3 (pl) | 2020-08-24 |
| EP3719029A1 (en) | 2020-10-07 |
| US10774108B2 (en) | 2020-09-15 |
| EP3224269B1 (en) | 2020-02-26 |
| US20230279043A1 (en) | 2023-09-07 |
| HRP20200840T1 (hr) | 2020-11-13 |
| LT3224269T (lt) | 2020-07-10 |
| ES2793237T3 (es) | 2020-11-13 |
| US20210017218A1 (en) | 2021-01-21 |
| JP7186259B2 (ja) | 2022-12-08 |
| JP2021130698A (ja) | 2021-09-09 |
| RS60343B1 (sr) | 2020-07-31 |
| HUE049014T2 (hu) | 2020-09-28 |
| US20250042934A1 (en) | 2025-02-06 |
| WO2016082789A1 (en) | 2016-06-02 |
| EP3224269A4 (en) | 2018-07-25 |
| US11945836B2 (en) | 2024-04-02 |
| EP3224269A1 (en) | 2017-10-04 |
| JP2023022187A (ja) | 2023-02-14 |
| SI3224269T1 (sl) | 2020-10-30 |
| CY1123200T1 (el) | 2021-10-29 |
| PT3224269T (pt) | 2020-06-01 |
| SMT202000276T1 (it) | 2020-07-08 |
| ME03749B (me) | 2021-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6893173B2 (ja) | Ｃｎｓ障害を処置するための組成物および方法 | |
| AU2022203444B2 (en) | Compositions and methods for treating CNS disorders | |
| JP6826615B2 (ja) | 向神経活性ステロイド、組成物、及びその使用 | |
| JP7012119B2 (ja) | Ｃｎｓ障害を処置するための組成物および方法 | |
| JP7049313B2 (ja) | Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法 | |
| JP6875996B2 (ja) | 神経刺激性ステロイド、組成物、およびその使用 | |
| JP2020189848A (ja) | Ｃｎｓ障害を処置するための組成物および方法 | |
| KR20210107050A (ko) | 3.알파.-히드록시-17.베타.-아미드 신경활성 스테로이드 및 그의 조성물 | |
| HK1236539B (en) | Compositions and methods for treating cns disorders | |
| HK1236539A1 (en) | Compositions and methods for treating cns disorders | |
| BR112019000578B1 (pt) | Compostos esteróides neuroativos c17, c20 e c21 substituídos, suas composições farmacêuticas e seus usos | |
| BR122022005124B1 (pt) | Compostos esteróides neuroativos c17, c20 e c21 substituídos, suas composições farmacêuticas, seus usos e kits | |
| BR122022005119B1 (pt) | Compostos esteróides neuroativos c17, c20 e c21 substituídos, suas composições farmacêuticas, seus usos e kits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200924 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201223 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210315 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210331 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210430 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210531 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6893173 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |